These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1404 related items for PubMed ID: 26506422

  • 1. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y, Harashima N, Tajima Y, Harada M.
    Oncotarget; 2015 Dec 08; 6(39):41902-15. PubMed ID: 26506422
    [Abstract] [Full Text] [Related]

  • 2. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A.
    Clin Cancer Res; 2007 Dec 01; 13(23):7191-8. PubMed ID: 18056200
    [Abstract] [Full Text] [Related]

  • 3. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis.
    Song JH, Kandasamy K, Kraft AS.
    J Biol Chem; 2008 Sep 05; 283(36):25003-13. PubMed ID: 18599488
    [Abstract] [Full Text] [Related]

  • 4. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
    Bai J, Sui J, Demirjian A, Vollmer CM, Marasco W, Callery MP.
    Cancer Res; 2005 Mar 15; 65(6):2344-52. PubMed ID: 15781649
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
    Jebahi A, Villedieu M, Pétigny-Lechartier C, Brotin E, Louis MH, Abeilard E, Giffard F, Guercio M, Briand M, Gauduchon P, Lheureux S, Poulain L.
    Cancer Lett; 2014 Jun 28; 348(1-2):38-49. PubMed ID: 24650799
    [Abstract] [Full Text] [Related]

  • 9. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein.
    Wang G, Zhan Y, Wang H, Li W.
    Cancer Chemother Pharmacol; 2012 Mar 28; 69(3):799-805. PubMed ID: 22037880
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak.
    Sun JG, Xiang J, Zeng XL, Li X, Wu P, Fung KP, Liu FY.
    Cancer Lett; 2014 Dec 28; 355(2):253-63. PubMed ID: 25304383
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening.
    Garimella SV, Gehlhaus K, Dine JL, Pitt JJ, Grandin M, Chakka S, Nau MM, Caplen NJ, Lipkowitz S.
    Breast Cancer Res; 2014 Apr 17; 16(2):R41. PubMed ID: 24745479
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R, Albarenque SM, Cool RH, Quax WJ, Mohr A, Zwacka RM.
    Cancer Biol Ther; 2014 Apr 17; 15(12):1658-66. PubMed ID: 25482930
    [Abstract] [Full Text] [Related]

  • 19. HIF-2α dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating survivin expression.
    Harashima N, Takenaga K, Akimoto M, Harada M.
    Oncotarget; 2017 Jun 27; 8(26):42887-42900. PubMed ID: 28476028
    [Abstract] [Full Text] [Related]

  • 20. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins.
    Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Böck BC, Macher-Goeppinger S, Radlwimmer B, Wiestler OD, Herold-Mende C, Roth W.
    Oncogene; 2008 Nov 06; 27(52):6646-56. PubMed ID: 18663354
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.